Biosimilar Drug Approved for Rheumatoid Arthritis

Less expensive versions of costly biologic drugs have arrived, and more are on the way.

Drug manufacturers have recently devised methods to make approximate copies of some biologic drugs that, while not exact, are similar enough to the original to have the same therapeutic effect. The FDA decided to accept these biosimilars as long as the drugs meet strict standards of efficacy and safety. So far, two have been approved in the United States-Zarxio (a biosimilar of filgrastim) for cancer and Inflectra (a biosimilar of infliximab). In Europe, there are 22 biosimilar drugs.
To continue reading this article or issue you must be a paid subscriber. Sign in

Subscribe to Arthritis Advisor

Get the next year of Arthritis Advisor for just $20. And access all of our online content - over 1,000 articles - free of charge.
Subscribe today and save 36%. It's like getting 4 months FREE!
Already Subscribed?
Click Here to Sign In | Forgot your password? | Activate Web Access